We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.78B
AUM Growth
+$18.3M
(+0.66%)
Cap. Flow
+$443M
Cap. Flow
% of AUM
15.93%
Top 10 Holdings %
Top 10 Hldgs %
42.27%
Holding
179
New
61
Increased
32
Reduced
13
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$37.6M |
| 2 |
UnitedHealth
UNH
|
+$37.4M |
| 3 |
United Therapeutics
UTHR
|
+$29.3M |
| 4 |
Merck
MRK
|
+$27.6M |
| 5 |
Agilent Technologies
A
|
+$24.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$27.7M |
| 2 |
CELG
Celgene Corp
CELG
|
+$26.8M |
| 3 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
+$26.5M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$23.7M |
| 5 |
ACOR
Acorda Therapeutics
ACOR
|
+$22.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.09% |
| 2 | Real Estate | 3.47% |
| 3 | Financials | 1.31% |
| 4 | Technology | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
CALL
Humana
HUM
$44B
| $10.5M | 0.38% |
+58,900
| New | +$10.9M |
|
52
Baxter International
BAX
$13.8B
| $10.5M | 0.38% |
319,600
-268,784
| -46% | -$10.2M |
|
53
CALL
Bristol-Myers Squibb
BMY
$132B
| $10.5M | 0.38% |
+177,200
| New | +$11.2M |
|
|
54
CALL
UnitedHealth
UNH
$383B
| $10.4M | 0.37% |
+89,700
| New | +$10.7M |
|
55
CALL
Incyte
INCY
$24.9B
| $10.3M | 0.37% |
+93,700
| New | +$10.5M |
|
|
STJ
56
DELISTED
St Jude Medical
STJ
| $10.2M | 0.37% |
161,510
| – | – |
|
|
SHPG
57
DELISTED
Shire pic
SHPG
| $10.2M | 0.37% |
+49,513
| New | +$11.8M |
|
|
LTC
58
LTC Properties
LTC
$2.06B
| $10.1M | 0.36% |
236,618
| – | – |
|
|
CELG
59
CALL
DELISTED
Celgene Corp
CELG
| $10.1M | 0.36% |
+93,300
| New | +$11.6M |
|
|
BXLT
60
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $10.1M | 0.36% |
+319,600
| New | +$11M |
|
61
Cigna
CI
$76.1B
| $10M | 0.36% |
74,251
| – | – |
|
|
62
CALL
Cigna
CI
$76.1B
| $10M | 0.36% |
+74,200
| New | +$10.8M |
|
63
Idexx Laboratories
IDXX
$44.1B
| $9.83M | 0.35% |
132,352
| – | – |
|
64
Karyopharm Therapeutics
KPTI
$159M
| $9.68M | 0.35% |
61,258
+29,460
| +93% | +$7.88M |
|
|
AGN
65
CALL
DELISTED
Allergan plc
AGN
| $9.68M | 0.35% |
+35,600
| New | +$10.9M |
|
66
Zimmer Biomet
ZBH
$18.4B
| $9.61M | 0.35% |
105,369
| – | – |
|
67
CALL
Alkermes
ALKS
$8.39B
| $9.57M | 0.34% |
+163,200
| New | +$10.8M |
|
|
AET
68
CALL
DELISTED
Aetna Inc
AET
| $9.22M | 0.33% |
+84,300
| New | +$9.74M |
|
69
Community Health Systems
CYH
$391M
| $8.96M | 0.32% |
253,582
| – | – |
|
70
AbbVie
ABBV
$455B
| $8.93M | 0.32% |
164,156
+164,000
| +105,128% | +$10.7M |
|
71
Natera
NTRA
$38.6B
| $8.84M | 0.32% |
+814,300
| New | +$13.8M |
|
|
MDVN
72
DELISTED
MEDIVATION, INC.
MDVN
| $8.73M | 0.31% |
205,400
+98,000
| +91% | +$4.85M |
|
|
GWPH
73
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $8.59M | 0.31% |
+94,000
| New | +$10.5M |
|
74
Novartis
NVS
$301B
| $8.52M | 0.31% |
+103,453
| New | +$9.21M |
|
75
Ultragenyx Pharmaceutical
RARE
$2.56B
| $8.51M | 0.31% |
88,400
+28,400
| +47% | +$3.25M |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q3 2015 Portfolio in Review
As of Q3 2015, Tekla Capital Management held 179 positions worth $2.78B, up 0.66% from $2.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Tekla Capital Management deployed $443M of net new capital in Q3 2015, opening 61 new positions and adding to 32 existing holdings. Its largest new stake was UnitedHealth: 312,600 shares worth $36.3M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Amgen, an estimated $27.7M trimmed.
- Tekla Capital Management's largest Q3 2015 buy was UnitedHealth: 312,600 shares worth $36.3M.
- Tekla Capital Management added most to Biogen in Q3 2015, an estimated $37.6M increase.
- Tekla Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $27.7M.
- Tekla Capital Management fully exited CATAMARAN CORP COM STK (CDA) in Q3 2015, selling an estimated $26.5M.
- Tekla Capital Management's ten largest holdings make up 42% of its $2.78B portfolio in Q3 2015.
- Tekla Capital Management opened 61 new positions and closed 19 in Q3 2015.
- Tekla Capital Management's portfolio value rose 0.66% quarter-over-quarter to $2.78B.
Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.